The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Muto et al., N Engl J Med 334(24):1561-1568 June 13, 1996.

Correspondence
PreviousPrevious
Volume 335:1460-1462 November 7, 1996 Number 19
NextNext

Polyprenoic Acid in Hepatocellular Carcinoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Muto, Y.
-Related Article
by Muto, Y.
To the Editor: We believe that more data are needed before polyprenoic acid can be accepted as an effective drug for the adjuvant treatment of hepatocellular carcinoma, as reported by Muto et al. (June 13 issue).1 We are concerned about several issues that were raised in the report. The authors claimed that tumors recurred in 27 percent of the group given polyprenoic acid (12 of 44) and 49 percent of the placebo group (22 of 45, P = 0.04). However, the Kaplan–Meier analysis in Figure 2 of the article shows a total of 24 patients (16 in the polyprenoic acid . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.